| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel | Sr. V.p. and General Counsel
2 companies
Rowland Lloyd A serves as a General Counsel at CTMX and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 7 sells. Those positions are worth an estimated $72K at current prices.
Historically, Rowland Lloyd A's trades have earned a middling insider score of 50/100 across 7 rated trades. Over a 12-month horizon, 42.9% of those trades were profitable, with an average 12-month return of -12.8%.
The biggest single holding is CTMX (~$72K) as General Counsel. The recent filings there lean toward selling, a net 27,854 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Sell | 10,203 | $0.60 | $6,111.60 | -7.8% | +307.5% | +628.8% | |
| Aug 20, 2024 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Sale+OE | 4,181 | $1.23 | $5,138.87 | -3.1% | -30.4% | +58.9% | |
| Mar 19, 2024 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Sell | 5,268 | $2.09 | $10,986.41 | -4.3% | -37.2% | -69.3% | |
| Dec 20, 2023 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Sell | 4,077 | $1.38 | $5,629.11 | -4.0% | +62.7% | -17.9% | |
| Sep 22, 2023 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Sell | 5,486 | $1.30 | $7,135.09 | -6.4% | +10.2% | -7.0% | |
| Mar 16, 2023 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Sell | 2,037 | $1.98 | $4,031.22 | -2.8% | -19.1% | +6.7% | |
| Jul 20, 2022 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Sell | 5,602 | $1.42 | $7,967.72 | -11.4% | -6.6% | +18.5% | |
| Mar 4, 2019 | CTMX Cytomx Therapeutics, Inc. | General Counsel | Buy | 9,000 | $10.33 | $92,970.00 | +919.3% | - | - |